Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: A children's oncology group study (ADVL0015)

Journal of Clinical Oncology

Volumn 22, Issue 23, 2004, Pages 4752-4757

  Blaney, Susan M ^a   Bernstein, Mark ^a   Neville, Kathleen ^a   Ginsberg, Jill ^a   Kitchen, Brenda ^a   Horton, Terzah ^a   Berg, Stacey L ^a   Krailo, Mark ^a   Adamson, Peter C ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PROTEASOME; PROTEASOME INHIBITOR;

ARTICLE; CANCER RECURRENCE; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG TOLERABILITY; ENZYME ACTIVITY; HUMAN; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TOXICITY;

EID: 16544389047     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.12.185     Document Type: Article

References (20)

1. King R, Deshaies R, Peters J-M, et al: How proteolysis drives the cell cycle. Science 274: 1652-1659, 1996
2. Adams J, Boyd M: Development of the proteasome inhibitor, PS-341. Oncologist 7:9-16, 2002
3. Fenteany G, Standaert R, Reichard G, et al: A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc Natl Acad Sci U S A 91:3358-3362, 1994
4. Omura S, Matsuzaki K, Fujimoto T: Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J Antibiot 44:117-118, 1991
5. Mugita N, Honda Y, Nakamura H: The involvement of proteasome in myogenic differentiation of murine myocytes and human rhabdomyosarcoma cells. Int J Mol Med 3:127-137, 1999
6. Soldatenkov V, Dritschilo A: Apoptosis of Ewing's sarcoma cells is accompanied by accumulation of ubiquitinated proteins. Cancer Res 57:3881-3885, 1997
7. Adams J, Palombella V, Sausville E, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999
8. Orlowski R, Stinchcombe T, Mitchell B, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002
9. Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511, 2002
10. Richardson P, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
11. Lightcap ES, McCormack TA, Pien C, et al: Proteasome inhibition measurements: Clinical applications. Clin Chem 46:673-683, 2000
12. Teicher B, Ara G, Herbst R, et al: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5:2368-2645, 1999
13. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001
14. Mitsiades N, Mitsiades C, Richardson P, et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 101:2377-2380, 2002
15. Cusack J Jr, Liu R, Houston M, et al: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappa B inhibition. Cancer Res 61:3535-3540, 2001
16. Shah S, Potter M, McDade T, et al: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82:110-122, 2001
17. Bold R, Virudachalam S, McConkey D: Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100: 11-17, 2001
18. Sayers T, Brooks A, Koh C, et al: The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102:303-310, 2003
19. Mimnaugh E, Xu W, Isaacs J, et al: Geldanamycin combined with PS-341 synergistically activates a cellular stress response, causes massive accumulation of ubiquitinated proteins and shows enhanced antitumor activity. Proc Am Assoc Cancer Res 43:179, 2003 (abstr 785)
20. Mitsiades C, Mitsiades N, Poulaki V, et al: Hsp90 inhibitors prolong survival in a SCID/NOD mouse model of diffuse multiple myeloma: Therapeutic implications. Proc Am Assoc Cancer Res 43:180, 2003 (abstr 788)